Latest Trials Latest NewsFAQ

ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: Risankizumab
Drug: Ustekinumab

First Posted Date: 2020-06-17

Last Posted Date: 2024-10-26

Lead Sponsor: AbbVie

Target Recruit Count: 150

Registration Number: NCT04435600

Locations: 🇩🇪
Universitaetsklinikum Carl Gustav Carus Dresden /ID# 228881, Dresden, Sachsen, Germany
🇯🇵
Duplicate_Teikyo University Hospital /ID# 255188, Itabashi-ku, Tokyo, Japan
🇬🇧
Duplicate_Royal Devon University Healthcare NHS Foundation Trust /ID# 228078, Exeter, Devon, United Kingdom

and more 50 locations

Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis

Recruiting

Conditions: Psoriasis
Psoriatic Arthritis

First Posted Date: 2020-06-16

Last Posted Date: 2024-10-03

Lead Sponsor: AbbVie

Target Recruit Count: 3000

Registration Number: NCT04433442

Locations: 🇰🇷
Dongguk University Ilsan Hospital /ID# 259337, Ilsan, Gyeonggido, Korea, Republic of
🇰🇷
Gachon University Gil Medical Center /ID# 262788, Incheon, Gyeonggido, Korea, Republic of
🇰🇷
Catholic Kwandong University International St.Mary's Hospital /ID# 262855, Incheon, Gyeonggido, Korea, Republic of

and more 60 locations

A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms

Phase 2

Completed

Conditions: Hidradenitis Suppurativa (HS)

Interventions: Drug: Upadacitinib
Drug: Placebo

First Posted Date: 2020-06-12

Last Posted Date: 2023-02-06

Lead Sponsor: AbbVie

Target Recruit Count: 68

Registration Number: NCT04430855

Locations: 🇺🇸
Medical Dermatology Specialist /ID# 221084, Phoenix, Arizona, United States
🇺🇸
Beth Israel Deaconess Medical Center /ID# 218306, Boston, Massachusetts, United States
🇯🇵
Takagi Dermatology Clinic /ID# 218587, Obihiro-shi, Hokkaido, Japan

and more 23 locations

Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia

Phase 1

Terminated

Conditions: Presbyopia

Interventions: Drug: AGN-241622
Drug: Vehicle

First Posted Date: 2020-05-27

Last Posted Date: 2024-02-06

Lead Sponsor: AbbVie

Target Recruit Count: 80

Registration Number: NCT04403763

Locations: 🇺🇸
Kannarr Eye Care /ID# 236718, Pittsburg, Kansas, United States
🇺🇸
North Valley Eye Medical Group, Inc. /ID# 236686, Mission Hills, California, United States
🇺🇸
The Eye Care Institute /ID# 234507, Louisville, Kentucky, United States

and more 7 locations

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

Phase 3

Active, not recruiting

Conditions: Myelodysplastic Syndrome (MDS)

Interventions: Drug: Venetoclax
Drug: Placebo
Drug: Azacitidine

First Posted Date: 2020-05-26

Last Posted Date: 2024-06-20

Lead Sponsor: AbbVie

Target Recruit Count: 531

Registration Number: NCT04401748

Locations: 🇺🇸
Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 223727, Dallas, Texas, United States
🇺🇸
UPMC Hillman Cancer Ctr /ID# 223201, Pittsburgh, Pennsylvania, United States
🇨🇳
China Medical University Hospital /ID# 218987, Taichung, Taiwan

and more 217 locations

Cariprazine Pediatric ASD PK Study

Phase 1

Completed

Conditions: Autism Spectrum Disorder

Interventions: Drug: Cariprazine

First Posted Date: 2020-05-11

Last Posted Date: 2022-04-12

Lead Sponsor: AbbVie

Target Recruit Count: 24

Registration Number: NCT04382885

Locations: 🇺🇸
Atlanta Center for Medical Research /ID# 233576, Atlanta, Georgia, United States
🇺🇸
iResearch Atlanta, LLC /ID# 233614, Decatur, Georgia, United States
🇺🇸
Neuropsychiatric Research Center of Orange County /ID# 233663, Orange, California, United States

Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease

Phase 3

Completed

Conditions: Parkinson's Disease (PD)

Interventions: Drug: ABBV-951
Drug: Levodopa/Carbidopa (LD/CD)
Drug: Placebo for Levodopa/Carbidopa (LD/CD)
Drug: Placebo for ABBV-951

First Posted Date: 2020-05-08

Last Posted Date: 2022-11-18

Lead Sponsor: AbbVie

Target Recruit Count: 174

Registration Number: NCT04380142

Locations: 🇺🇸
University of California, Los Angeles /ID# 216674, Los Angeles, California, United States
🇺🇸
Parkinson's Disease and Movement Disorders Center of Boca Raton /ID# 216517, Boca Raton, Florida, United States
🇺🇸
Brain Matters Research /ID# 217089, Delray Beach, Florida, United States

and more 73 locations

Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease

Phase 3

Active, not recruiting

Conditions: Parkinson's Disease (PD)

Interventions: Drug: ABBV-951

First Posted Date: 2020-05-07

Last Posted Date: 2024-06-18

Lead Sponsor: AbbVie

Target Recruit Count: 130

Registration Number: NCT04379050

Locations: 🇺🇸
Washington University-School of Medicine /ID# 215472, Saint Louis, Missouri, United States
🇺🇸
Central Texas Neurology Consul /ID# 217013, Round Rock, Texas, United States
🇺🇸
Booth Gardner Parkinson's Care Center /ID# 215535, Kirkland, Washington, United States

and more 48 locations

Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury

Phase 2

Completed

Conditions: CoronaVirus Induced Disease-2019 (COVID-19)

Interventions: Drug: Placebo
Drug: Ibrutinib

First Posted Date: 2020-05-05

Last Posted Date: 2022-06-01

Lead Sponsor: AbbVie

Target Recruit Count: 46

Registration Number: NCT04375397

Locations: 🇺🇸
Stanford University School of Med /ID# 221954, Stanford, California, United States
🇺🇸
Midway Immunology and Research /ID# 222004, Fort Pierce, Florida, United States
🇺🇸
Triple O Research Institute /ID# 222944, West Palm Beach, Florida, United States

and more 6 locations

A Study Describing the Care Cascade and Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adult Participants With Hepatitis C Virus in French Addiction Centers

Completed

Conditions: Hepatitis C Virus (HCV)

First Posted Date: 2020-04-29

Last Posted Date: 2024-02-01

Lead Sponsor: AbbVie

Target Recruit Count: 95

Registration Number: NCT04366973

Locations: 🇫🇷
Association Tremplin 17 - Saintes /ID# 218708, Saintes, Nouvelle-Aquitaine, France
🇫🇷
Centre de soin d'accompagnement et de prevention en addictologie-Paul Guiraud /ID# 218710, Bagneux, Ile-de-France, France
🇫🇷
CEID Bearn addictions /ID# 221279, Pau, France

and more 27 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy